Novo Nordisk A/S $NVO Shares Sold by Saratoga Research & Investment Management

Saratoga Research & Investment Management trimmed its holdings in Novo Nordisk A/S (NYSE:NVO) by 5.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,236,009 shares of the company’s stock after selling 200,320 shares during the quarter. Novo Nordisk A/S comprises 8.5% of Saratoga Research & Investment Management’s portfolio, making the stock its 2nd largest holding. Saratoga Research & Investment Management’s holdings in Novo Nordisk A/S were worth $155,134,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in NVO. Godfrey Financial Associates Inc. bought a new stake in Novo Nordisk A/S during the 4th quarter valued at $25,000. Scarborough Advisors LLC bought a new position in shares of Novo Nordisk A/S in the first quarter worth $26,000. WealthCollab LLC grew its stake in shares of Novo Nordisk A/S by 93.5% in the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after purchasing an additional 260 shares in the last quarter. Jackson Grant Investment Advisers Inc. acquired a new position in shares of Novo Nordisk A/S during the fourth quarter valued at $29,000. Finally, Quaker Wealth Management LLC increased its holdings in shares of Novo Nordisk A/S by 186.0% during the fourth quarter. Quaker Wealth Management LLC now owns 615 shares of the company’s stock valued at $31,000 after purchasing an additional 400 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Up 0.8%

Shares of NYSE NVO opened at $46.75 on Friday. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $64.16. The company has a market cap of $208.74 billion, a price-to-earnings ratio of 11.43, a P/E/G ratio of 4.23 and a beta of 0.76. The business has a fifty day simple moving average of $47.30 and a 200-day simple moving average of $44.50.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. The company had revenue of $11.98 billion for the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 61.20%. Sell-side analysts predict that Novo Nordisk A/S will post 3.39 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently disclosed a dividend, which will be paid on Tuesday, August 25th. Investors of record on Monday, August 17th will be paid a $0.5786 dividend. This represents a yield of 254.0%. The ex-dividend date of this dividend is Monday, August 17th. Novo Nordisk A/S’s dividend payout ratio is currently 42.79%.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. BMO Capital Markets restated a “market perform” rating and set a $47.00 price objective on shares of Novo Nordisk A/S in a research note on Thursday, August 6th. Citigroup reissued a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, July 20th. HSBC restated a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. Berenberg Bank set a $47.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday. Finally, Weiss Ratings raised Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. Four equities research analysts have rated the stock with a Buy rating and sixteen have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $64.94.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: CEO Mike Doustdar said the obesity-drug market will not be “winner-take-all,” arguing that patients’ differing preferences and demand for pills, injectables and other differentiated treatments should support multiple successful players. Reuters article
• Positive Sentiment: Novo’s oral Wegovy appears to be generating strong prescription momentum, offering a potential new growth channel and helping the company compete beyond its injectable portfolio. However, investors are watching whether that momentum can offset Lilly’s faster growth. Zacks article
• Positive Sentiment: Zacks Research upgraded NVO from “strong sell” to “hold,” indicating that the stock’s sharp decline and low earnings multiple may have reduced some downside risk.
• Neutral Sentiment: Novo defended its lawsuit challenging Eli Lilly’s weight-loss advertising, saying competition must be fair. The litigation could protect Novo’s marketing position, but it also highlights the intensity of the competitive battle. CNBC article
• Neutral Sentiment: Novo’s CEO continues to promote a long runway for obesity treatments, citing low overall adoption and potential healthcare-cost benefits. These are long-term opportunities rather than immediate earnings catalysts. Fox Business article
• Negative Sentiment: Eli Lilly’s growing share in both injectable and oral weight-loss drugs is the main concern. Analysts warn that Lilly’s momentum could widen the competitive gap and limit the upside investors had anticipated from the Wegovy pill. Yahoo Finance article
• Negative Sentiment: Berenberg downgraded Novo from “buy” to “hold,” citing expectations that the initial Wegovy-pill upside is already reflected in the stock and valuing the company closer to the broader European pharmaceutical sector.
• Negative Sentiment: Recent analysis also points to flat Wegovy sales, pricing pressure and pipeline setbacks as near-term risks, helping explain why NVO has decreased despite its strong margins and broader cardiometabolic pipeline. Zacks analysis

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.